Investigating Bioequivalence Between Single-dose Liraglutide Administered Subcutaneously With Two Different Pen-injectors

NCT02207348 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Metabolism and Nutrition Disorder
Obesity

Interventions

DRUG: liraglutide

Sponsor

Novo Nordisk A/S